Literature DB >> 24078503

Cytosolic HMGB1 expression in human renal clear cell cancer indicates higher pathological T classifications and tumor grades.

Takumi Takeuchi1, Koichi Sakazume, Akiko Tonooka, Masayoshi Zaitsu, Yuta Takeshima, Koji Mikami, Toshimasa Uekusa.   

Abstract

PURPOSE: High mobility group box (HMGB) proteins are nuclear nonhistone chromosomal proteins that bend DNA, bind preferentially to distorted DNA structures, and promote the assembly of site-specific DNA binding proteins. Recent reports indicate that HMGB1 functions as a proinflammatory cytokine. Here, we studied expressions of HMGB1 and HMGB2 in human renal cancer.
MATERIAL AND METHODS: Immunohistological expressions of HMGB1 and HMGB2 were assessed in 39 surgically resected human renal cancer specimens.
RESULTS: HMGB1 was expressed in the nucleus in 37 out of 39 (94.9%) renal clear cell cancers,while its expression in the cytosol was noted in 19 cases (48.7%). Cytosolic HMGB1 is expressed more frequently in cancers beyond the pT1b classification than in those at the pT1a classification. Higher tumor grades (≥ G2) were also significantly linked with the cytosolic expression of HMGB1. HMGB2 was expressed in the nucleus in 35 of 39 (89.7%) renal clear cell cancers, while its expression in the cytosol was observed in only 7 case (17.9%). Linkage between cytosolic expression of HMGB2 and T classifications was weakly observed, while that between nuclear expression and T classifications was not.
CONCLUSION: HMGB1 expressed in the cytoplasm may be an effective marker indicating higher T classifications and tumor grades.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24078503

Source DB:  PubMed          Journal:  Urol J        ISSN: 1735-1308            Impact factor:   1.510


  10 in total

1.  The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma.

Authors:  Toru Takeda; Hiroto Izumi; Shohei Kitada; Hidetaka Uramoto; Takashi Tasaki; Li Zhi; Xin Guo; Yuichiro Kawatsu; Tomoko Kimura; Seichi Horie; Atsunori Nabeshima; Hirotsugu Noguchi; Ke-Yong Wang; Yasuyuki Sasaguri; Kimitoshi Kohno; Sohsuke Yamada
Journal:  Tumour Biol       Date:  2014-07-26

Review 2.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

3.  Long noncoding RNA CRCMSL suppresses tumor invasive and metastasis in colorectal carcinoma through nucleocytoplasmic shuttling of HMGB2.

Authors:  Qinrui Han; Lijun Xu; Weihao Lin; Xueqing Yao; Muhong Jiang; Rui Zhou; Xuegang Sun; Liang Zhao
Journal:  Oncogene       Date:  2018-12-21       Impact factor: 9.867

Review 4.  The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases.

Authors:  Qingjie Chen; Xiaofeng Guan; Xiaocong Zuo; Jianglin Wang; Wenjun Yin
Journal:  Acta Pharm Sin B       Date:  2016-03-07       Impact factor: 11.413

Review 5.  The Role of HMGB1 Signaling Pathway in the Development and Progression of Hepatocellular Carcinoma: A Review.

Authors:  Xuanbin Wang; Longchao Xiang; Hongliang Li; Ping Chen; Yibin Feng; Jingxuan Zhang; Nian Yang; Fei Li; Ye Wang; Quifang Zhang; Fang Li; Fengjun Cao
Journal:  Int J Mol Sci       Date:  2015-09-17       Impact factor: 5.923

6.  Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development.

Authors:  Julia Schueler; Kerstin Klingner; Daniel Bug; Caren Zoeller; Armin Maier; Meng Dong; Kerstin Willecke; Anne-Lise Peille; Eva Steiner; Manuel Landesfeind; John A Copland; Gabrielle M Siegers; Axel Haferkamp; Katharina Boehm; Igor Tsaur; Meike Schneider
Journal:  Oncotarget       Date:  2018-07-24

7.  Comprehensive analysis of somatic copy number alterations in clear cell renal cell carcinoma.

Authors:  Takashi Tsuyukubo; Kazuyuki Ishida; Mitsumasa Osakabe; Ei Shiomi; Renpei Kato; Ryo Takata; Wataru Obara; Tamotsu Sugai
Journal:  Mol Carcinog       Date:  2020-02-10       Impact factor: 4.784

8.  Occupational disparities in tumor grade and cytosolic HMGB1 expression in renal cell cancer.

Authors:  Masayoshi Zaitsu; Takumi Takeuchi; Masaaki Zaitsu; Akiko Tonooka; Toshimasa Uekusa; Yudai Miyake; Yasuki Kobayashi; Gen Kobashi; Ichiro Kawachi
Journal:  J Occup Health       Date:  2022-01       Impact factor: 2.570

9.  HMGB1 Translocation is Associated with Tumor-Associated Myeloid Cells and Involved in the Progression of Fibroblastic Sarcoma.

Authors:  Huoying Chen; Xiaoying Lin; Hongbo Liu; Cheng Huang; Rong Li; Jie Ai; Jiaxue Wei; Shengjun Xiao
Journal:  Pathol Oncol Res       Date:  2021-03-31       Impact factor: 3.201

10.  HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2.

Authors:  Yanmei Chen; Chengzhao Lin; Yang Liu; Yan Jiang
Journal:  Tumour Biol       Date:  2015-10-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.